ERBB2 and breast carcinoma: Breast cancer is biologically heterogeneous, and intrinsic molecular subtypes derived from gene-expression profiling—luminal A, luminal B, HER2-enriched and basal-like/triple-negative—have distinct patterns of recurrence and responsiveness to systemic therapy [27,28].